In a new study, Broad Institute researchers report that two small-molecule chemicals that reduce oxygen delivery to cells ...
I was hospitalized for a week in May of my junior year of college due to gastroenteritis, but I was able to be discharged ...
Daphne’s body tells the story of just how much she has endured. After living in horrific conditions surrounded by rubbish and ...
Jordan Routch had never heard of Friedreich’s ataxia, but he’s running the Buffalo Creek half marathon to raise awareness ...
When I first developed autonomic ataxia, I lived my life thinking only about recovering my physical health.Although I am ...
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced ...
Since acquiring the global rights to edaravone, a treatment for amyotrophic lateral sclerosis (ALS), known as RADICAVA ® in ...
Researchers have identified covert deletions of the proximal FXN gene that standard testing mistakes for identical repeat ...
The pair started competing in powerlifting roughly five years before now, according to The Virginian-Pilot. Both deal with muscle incoordination and slurred speech as part of their respective ...
A year-long Dutch study shows the PROM-Ataxia questionnaire validly captures disease burden in spinocerebellar ataxia, even ...
A monthly snapshot of FDA activity involving therapies used in the prevention, diagnosis, and treatment of neurologic conditions.
Shionogi will acquire IntraBio for $2 billion upfront, adding AQNEURSA for rare neurological diseases. See what the deal means for its portfolio. Read more.